CurrentCapital BluecrossPolicy MP 2.308

Genetic testing for Helicobacter pylori treatment

This policy addresses the use of CYP2C19 genotyping to guide proton-pump inhibitor selection or dosing for H. pylori infection management for members of Capital Blue Cross products to which the policy applies.

Policy Summary

PayerCapital Bluecross

PolicyGenetic testing for Helicobacter pylori treatment

Policy CodePolicy MP 2.308

Change TypeAdministrative and consensus updates (2023–2025)

Effective Date12/1/2025

Next Review Date

Key ActionDo not order CYP2C19 genotyping to guide H. pylori treatment; this use is investigational and not covered.

SourceLink

POLICY UPDATE CHANGES

Clinical benefit added.

Removed Benefit Variations Section and updated Disclaimer.

Updated background and references; coding reviewed with no changes.

Investigationalcoverage stance

81225not covered code

12/1/2025effective

Multiple reviewshistory

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Investigational / Not covered

Covered when ALL of the following are met

Investigational stance: Genotyping to determine CYP2C19 genetic polymorphisms is considered investigational for the purpose of managing the treatment of H. pylori infection; there is insufficient evidence that pharmacogenomics‑based regimens improve eradication rates or health outcomes.

Policy statement - not covered

Genetic testing to determine CYP2C19 polymorphisms for the purpose of managing treatment of Helicobacter pylori infection is considered investigational and is not covered. The evidence is insufficient to demonstrate improved health outcomes from pharmacogenomics-guided regimens for H. pylori eradication.

The excerpt does not list any explicit exclusion conditions beyond the investigational determination. Coverage is determined by member benefit terms and applicable product variations.

Rationale: available studies do not permit definitive conclusions that pharmacogenomics-based H. pylori treatment regimens improve eradication rates or health outcomes. Variability in treatment protocols, potential influence of other clinical factors (for example, clarithromycin resistance), and limited trial data prevent attributing benefit specifically to CYP2C19-directed PPI selection or dosing; therefore use of genetic testing for H. pylori treatment is investigational.

There are no explicit statements within this excerpt that characterize any testing related to H. pylori management as not medically necessary beyond the investigational/not covered designation.

Genetic testing related to Helicobacter pylori treatment

Policy title indicates coverage domain; specific covered indications are not provided in this excerpt.

Title/Scope: Genetic testing related to Helicobacter pylori treatment (see policy MP 2.308).

Policy addresses CYP2C19 genotyping in the context of H. pylori treatment but does not list covered indications in the provided text.

Not Covered

CYP2C19 genotyping to guide H. pylori treatment is investigational and not covered. Reportable procedure code associated with this investigational determination is 81225.

No additional specific tests or clinical indications are listed as excluded in the provided excerpt beyond the investigational status for CYP2C19-directed management.

Coding

Investigational / Not covered procedure codesCPTNot Covered

81225

Procedure code listed (genetic testing) as investigational; therefore not covered for H. pylori management

Population prevalence examples — CYP2C19 polymorphism prevalence by population

Heterozygous CYP2C19 polymorphisms (intermediate metabolizers)27–37% in Caucasians; 46–50% in Asians.

Homozygous CYP2C19 polymorphisms (poor metabolizers)3–6% in Caucasians; 12–20% in Asians.

Extensive metabolizers (no polymorphisms)Individuals with two wild‑type (*1) alleles and normal PPI metabolism.

Phenotype impact on intragastric pHPoor metabolizers (homozygous mutations) have less acidic intragastric pH; heterozygotes have intermediate pH, correlating with PPI response.

Provider Actions & Billing Notes

Note

Provider Actions & Billing Notes

This policy is applicable only to certain programs and products issued or administered by Capital Blue Cross and/or its subsidiaries (Capital Advantage Insurance Company®, Capital Advantage Assurance Company®, and Keystone Health Plan® Central). Benefit variations may exist between programs; final claim processing and coverage determinations are governed by the member's specific health care benefit program, the terms of the contract that applies to the member, benefit limitations and exclusions, and a medical necessity determination.

Program/product applicability: Policy applies only to certain Capital Blue Cross programs and products; benefit variations may exist.
Coverage governance: Coverage and claim payment are governed by the terms of the member's health care benefit program and Capital Blue Cross (and subsidiaries) administration; services must be medically necessary and appropriate.
Policy applies to health care benefit programs issued or administered by Capital Blue Cross and its subsidiaries (Capital Advantage Insurance Company®, Capital Advantage Assurance Company®, Keystone Health Plan® Central).
Claims note: These medical policies are not a guarantee of coverage or payment—final processing is subject to member eligibility, benefit program rules, and medical necessity determination. If there are questions, contact Capital Blue Cross Provider Services or Member Services.

Background

Background: Treatment of H. pylori infection combines antibiotics with a proton‑pump inhibitor (PPI). CYP2C19 genetic polymorphisms affect PPI metabolism and therefore intragastric acid suppression; poor metabolizers typically achieve greater acid suppression and higher eradication rates, whereas extensive metabolizers may have lower eradication rates. These pharmacogenomic differences have prompted investigation into tailoring PPI choice or dose by genotype, but current evidence is insufficient to support routine genotype-guided therapy.

Definitions

GENOTYPE definition

DefinitionGENOTYPE: the pair of genes present for a particular characteristic or protein.

ContextRefers to the specific alleles an individual carries (e.g., CYP2C19 *1, *2, *3) that determine metabolic phenotype.

Clinical relevanceGenotype predicts enzymatic activity (extensive, intermediate, poor metabolizer) affecting drug metabolism.

POLYMORPHISM definition

DefinitionPOLYMORPHISM: the state or quality of existing or occurring in several different forms.

ExampleCYP2C19 *2 and *3 are common polymorphisms that result in loss of enzymatic activity.

Revision History

2025-09-23administrative_updateLatest

Removed Benefit Variations section and updated Disclaimer.

2025-08-08consensus_review

Consensus review; no change to policy statement; coding reviewed with no changes.

2024-01-19administrative_update

Administrative update: clinical benefit added.